Pregnancy, lupus and antiphospholipid syndrome (Hughes syndrome).
Autoimmune diseases (AD) occur frequently in women during their childbearing years and may influence pregnancy outcome and neonatal health. Patients with systemic lupus erythematosus (SLE) can experience a disease flare-up during pregnancy with potential negative effects on the product of conceptus, especially if the disease is active. Recurrent pregnancy loss is now considered as a treatable clinical condition associated with the presence of circulating antiphospholipid antibodies (aPL). The neonatal lupus syndromes (NLS), caused by the transplacental passage of maternal IgG anti-Ro/SS-A and anti-La/SS-B antibodies to the fetus, carry significant morbidity and mortality in case of cardiac manifestations. Immunosuppressive agents are often administered during pregnancy in order to control maternal disease and to ensure a better pregnancy outcome. Nowadays, owing to our increasing knowledge of the disease pathophysiological mechanisms and the development of combined medical-obstetric clinics, pregnancy outcome in patients with AD has notably improved.
Tincani
A
A
Rheumatology and Clinical Immunology, Brescia Hospital and University, Italy. tincani@bresciaseumatologia.it
Bompane
D
D
Danieli
E
E
Doria
A
A
D000974:Antibodies, Antinuclear / Q000097:blood*; D016736:Antiphospholipid Syndrome / Q000150:complications* / Q000628:therapy; D005260:Female; D006327:Heart Block / Q000151:congenital*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007231:Infant, Newborn; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000628:therapy; D011247:Pregnancy; D011248:Pregnancy Complications / Q000628:therapy; D013577:Syndrome
D000974:Antibodies, Antinuclear; D007166:Immunosuppressive Agents; C035356:SS-A antibodies